A novel semi‐mechanistic tumor growth fraction model for translation of preclinical efficacy of anti‐glypican 3 antibody drug conjugate to human

2020 ◽  
Vol 41 (8-9) ◽  
pp. 319-333
Author(s):  
Renu Singh ◽  
Alexander Kozhich ◽  
Chin Pan ◽  
Francis Lee ◽  
Pina Cardarelli ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Growth Fraction ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Preclinical Efficacy ◽  
Antibody Drug

Abstract 210: Novel antibody drug conjugate to inhibit mesothelioma tumor growth

2019 ◽  
Author(s):  
Jorge Marquez ◽  
Chun Dong ◽  
Jianping Dong ◽  
Binbin Yue ◽  
Ginette Serrero
Keyword(s):  
Tumor Growth ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

2016 ◽  
Vol 76 (21) ◽  
pp. 6331-6339 ◽  
Author(s):  
Anette Sommer ◽  
Charlotte Kopitz ◽  
Christoph A. Schatz ◽  
Carl F. Nising ◽  
Christoph Mahlert ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Preclinical Efficacy ◽  
Antibody Drug

Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 3066-3066 ◽  
Author(s):  
Esther CW Breij ◽  
Sandra Verploegen ◽  
Andreas Lingnau ◽  
Edward N van den Brink ◽  
Maarten Janmaat ◽  
...  
Keyword(s):  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Preclinical Efficacy ◽  
Efficacy Studies ◽  
Antibody Drug

Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma

2015 ◽  
Vol 21 (24) ◽  
pp. 5552-5562 ◽  
Author(s):  
Minh Nguyen ◽  
Shuichi Miyakawa ◽  
Junichi Kato ◽  
Toshiyuki Mori ◽  
Toshimitsu Arai ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Safety Assessment ◽  
Efficacy And Safety ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Preclinical Efficacy ◽  
Antibody Drug

A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo

2008 ◽  
Vol 68 (22) ◽  
pp. 9367-9374 ◽  
Author(s):  
Dowdy Jackson ◽  
John Gooya ◽  
Shenlan Mao ◽  
Krista Kinneer ◽  
Linda Xu ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Human Antibody ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals Antibody–Drug Conjugate to Treat Meningiomas

2021 ◽  
Vol 14 (5) ◽  
pp. 427
Author(s):  
Kai Chen ◽  
Yingnan Si ◽  
Jianfa Ou ◽  
Jia-Shiung Guan ◽  
Seulhee Kim ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Imaging System ◽  
Somatostatin Receptor ◽  
Antibody Drug Conjugate ◽  
Primary Tumors ◽  
Drug Conjugate ◽  
Binding Rate ◽  
Antibody Drug

Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control meningiomas. This study aimed to develop and evaluate an anti-SSTR2 antibody–drug conjugate (ADC) to target and treat meningiomas. The meningioma targeting, circulation stability, toxicity, and anti-tumor efficacy of SSTR2 ADC were evaluated using cell lines and/or an intracranial xenograft mouse model. The flow cytometry analysis showed that the anti-SSTR2 mAb had a high binding rate of >98% to meningioma CH157-MN cells but a low binding rate of <5% to the normal arachnoidal AC07 cells. The In Vivo Imaging System (IVIS) imaging demonstrated that the Cy5.5-labeled ADC targeted and accumulated in meningioma xenograft but not in normal organs. The pharmacokinetics study and histological analysis confirmed the stability and minimal toxicity. In vitro anti-cancer cytotoxicity indicated a high potency of ADC with an IC50 value of <10 nM. In vivo anti-tumor efficacy showed that the anti-SSTR2 ADC with doses of 8 and 16 mg/kg body weight effectively inhibited tumor growth. This study demonstrated that the anti-SSTR2 ADC can target meningioma and reduce the tumor growth.

Sign in / Sign up

Export Citation Format

Share Document